Peptides are easy to synthesize and optimize combinations, and their medicinal value can be quickly determined. Due to its properties, peptides take much less time from clinical trials to FDA approval than small molecule drugs, averaging about 10 years. Polypeptides are twice as likely to pass clinical trials as small molecular compounds.
The specific advantages of peptides make it demonstrate specific advantages in drug development and have clinical application value.
The half -life of peptides is generally short and unstable. Peptide drugs are easy to degrade quickly in the body, polypeptide preparations need to be kept at low temperature, but by modifying modification or forming a stable compound with other materials, can improve stability. Relatively large molecular proteins or antibodies, peptides are more stable at room temperature, with less dosage and higher unit activity.